"Cell"

The FDA has granted accelerated approval to Adagrasib for the treatment of patients with KRAS G12C mutations in non-small cell lung cancer. In the trial, the drug resulted in disease control in 80% of patients, of which, 43% had substantial tumour shrinkage.

Science has published two consecutive research articles that suggest new ways to improve the efficacy of CAR-T for solid tumours.

The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial

The US FDA has approved a new leukaemia drug, Olutasidenib, which has been shown to be effective and has a controlled safety profile, resulting in the complete disappearance of cancer cells in 35% of patients enrolled, with efficacy lasting up to 25.9 months.

A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.

A cutting-edge study from the University of California, San Francisco, recently showed that researchers have been able to make immune cells, which already recognize cancer cells, more powerful and durable through CRISPR gene editing tools, promising to become tireless, cold-blooded "cancer killers"!